Results 121 to 130 of about 756,046 (308)

Indometh acin-antihistamine combination for gastric ulceration control [PDF]

, 1980
An anti-inflammatory and analgesic composition containing indomethacin and an H2 histamine receptor antagonist in an amount sufficient to reduce gastric distress caused by the indomethacin was developed.
Brown, P. A., Vernikos, J.
core   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients

Pharmacy Practice, 2018
Objective: The objective of this study is to compute the potential benefit of Pramipexole ER on total levodopa equivalent dose (LED) and Unified Parkinson Disease Rating Score (UPDRS-III) compared to mono- or combined therapy of pramipexole IR and/or ...
Faddoul L, Chahine B, Haydar S, Abourida S, Hallit S, Bou Raad E.   +5 more
doaj   +1 more source

Meta‐Regression of a Dose‐Response Relationship of Methotrexate in Mono‐ and Combination Therapy in Disease‐Modifying Antirheumatic Drug–Naive Early Rheumatoid Arthritis Patients

Arthritis Care & Research, 2017
ObjectiveTo investigate a possible short‐term dose‐response relationship of initial treatment with methotrexate (MTX) in monotherapy and combination therapy in recent‐onset rheumatoid arthritis (RA) patients.MethodsA systematic literature search was performed on trials and cohorts, including early, disease‐modifying antirheumatic drug (DMARD)–naive RA ...
Bergstra, S.A., Allaart, C.F., Stijnen, T., Landewe, R.B.M.   +3 more
openaire   +3 more sources

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Comparing Two Different Doses of Intravenous Midazolamin in Pediatric Sedation and Analgesia

Emergency, 2016
Introduction: Midazolam has turned into a common drug for pediatric procedural sedation and analgesia. However, there is not much data regarding its proper dose and potential side effects in the Iranian children population.
Hassan Barzegari, Arash Forouzan, Kambiz Masoumi, Hassan Motamed, Behzad Zohrevandi, Shima Zeynadini Meymand   +5 more
doaj  

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Effects of staff education and standardizing dosing and collection times on vancomycin trough appropriateness in ward patients

Pharmacy Practice, 2017
Background: Many institutions have guidelines for initiation and monitoring, but not timing, of vancomycin. Objective: Our objective was to evaluate vancomycin trough collection appropriateness before and after an initiative to change the dosing and ...
Hammond DA, Atkinson LN, James TB, Painter JT, Lusardi K   +4 more
doaj   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Clinical Models to Compare the Safety and Efficacy of Inhaled Corticosteroids in Patients with Asthma

Canadian Respiratory Journal, 2003
There is no consensus on the methods to compare the clinical efficacy of different inhaled corticosteroids. A comparison needs to be made in terms of relative potency, and studies should include two-, or preferably, three-dose comparisons.
Krishnan Parameswaran, Richard Leigh, Paul M O'Byrne, Margaret M Kelly, Charlie H Goldsmith, Frederick E Hargreave, Myrna Dolovich   +6 more
doaj   +1 more source